Table 1.
Propensity score weighted Cox model: All cancers.
| Variable | All Follow Up HR (95% CI) | 1 yr HR (95% CI) | 2 yr HR (95% CI) |
|---|---|---|---|
| FLX +PD-1/L1 vs. PD-1/L1 alone | 0.59 (0.371–0.936) | 0.606 (0.362–1.015) | 0.6 (0.376–0.958) |
| Age | 1.002 (0.997–1.008) | 1.001 (0.995–1.008) | 1.002 (0.997–1.008) |
| Race: Other/unknown vs. Black | 1.569 (1.188–2.072) | 1.781 (1.331–2.382) | 1.587 (1.195–2.108) |
| White vs. Black | 1.282 (1.128–1.456) | 1.33 (1.137–1.555) | 1.258 (1.103–1.435) |
| Sex: Male vs. Female | 0.958 (0.703–1.306) | 1.056 (0.711–1.571) | 0.977 (0.703–1.357) |
| BMI: 18.5–24.9 vs. <18.5 | 0.779 (0.648–0.936) | 0.85 (0.678–1.066) | 0.809 (0.666–0.983) |
| 25–29.9 vs. <18.5 | 0.655 (0.543–0.79) | 0.691 (0.547–0.874) | 0.678 (0.554–0.829) |
| 30+ vs. <18.5 | 0.669 (0.55–0.814) | 0.687 (0.538–0.878) | 0.684 (0.554–0.844) |
| Missing vs. <18.5 | 1.498 (0.498–4.504) | 2.377 (0.991–5.704) | 1.724 (0.61–4.868) |
| Depression | 0.978 (0.869–1.101) | 0.988 (0.86–1.136) | 0.989 (0.876–1.117) |
| Charlson comorbidity index | 1.051 (1.036–1.067) | 1.06 (1.042–1.08) | 1.056 (1.04–1.072) |
| seer summary: localized vs. distant metastasis | 0.978 (0.841–1.137) | 0.841 (0.701–1.009) | 0.943 (0.804–1.106) |
| Regional vs. distant metastasis | 0.938 (0.837–1.052) | 0.863 (0.753–0.989) | 0.894 (0.793–1.007) |
| ECOG performance at diagnosis ECOG 1vs. 0 | 1.06 (0.953–1.179) | 1.088 (0.957–1.238) | 1.076 (0.963–1.203) |
| ECOG 2 vs. 0 | 1.277 (1.084–1.505) | 1.379 (1.14–1.668) | 1.281 (1.077–1.523) |
| ECOG 3 vs. 0 | 1.544 (1.134–2.102) | 1.748 (1.278–2.39) | 1.54 (1.118–2.12) |
| ECOG 4 vs. 0 | 1.971 (0.784–4.956) | 2.081 (0.805–5.383) | 2.194 (0.951–5.062) |
| Liver vs. Kidney/other urinary | 1.627 (1.212–2.185) | 1.696 (1.205–2.388) | 1.704 (1.269–2.287) |
| Lung vs. Kidney/other urinary | 1.631 (1.356–1.961) | 1.699 (1.341–2.151) | 1.668 (1.37–2.031) |
| Skin vs. Kidney/other urinary | 0.699 (0.538–0.909) | 0.861 (0.622–1.191) | 0.705 (0.531–0.937) |
| Throat vs. Kidney/other urinary | 1.487 (1.151–1.919) | 1.471 (1.067–2.026) | 1.529 (1.172–1.994) |
| Year of PD-1/PD-L1 start | 0.85 (0.811–0.892) | 0.924 (0.874–0.977) | 0.877 (0.834–0.922) |
| AVELUMAB | 0.8 (0.156–4.116) | 0.975 (0.209–4.545) | 0.882 (0.174–4.464) |
| DURVALUMAB | 0.241 (0.151–0.386) | 0.169 (0.092–0.309) | 0.252 (0.157–0.406) |
| NIVOLUMAB | 0.811 (0.591–1.113) | 0.739 (0.536–1.019) | 0.813 (0.59–1.12) |
| PEMBROLIZUMAB | 0.66 (0.476–0.914) | 0.588 (0.422–0.819) | 0.66 (0.475–0.918) |
| Total prior TX 2 vs. 1 | 1.153 (1.028–1.295) | 1.122 (0.979–1.286) | 1.154 (1.023–1.302) |
| 3 vs. 1 | 1.091 (0.812–1.465) | 1.12 (0.792–1.585) | 1.122 (0.824–1.526) |
| 0 vs. 1 | 0.928 (0.763–1.129) | 0.952 (0.755–1.201) | 0.938 (0.764–1.15) |